5. Eikon Therapeutics: $517.8 million (Biopharma)
Eikon Therapeutics will move to Millbrae, California, in 2024 when its new 285,000-square-foot headquarters building is completed. [Image courtesy of Eikon Therapeutics]
To do so, the Hayward, California-based company said it is combining advanced imaging tools, high-performance computing, molecular and cell biology, medicinal chemistry and robotics.
The company was started in 2019 based on super-resolution microscopy by co-founders Eric Betzig — whose work in the field won the Nobel Prize in Chemistry in 2014 — Xavier Darzacq, Luke Lavis and Robert Tjian.
“Through the integration of advanced engineering and high-performance computing, alongside more traditional molecular biology and medicinal chemistry, Eikon is developing a battery of innovative tools for biological exploration,” Eikon CEO and Chair Dr. Roger Perlmutter said when announcing the Series B round. “With the support of our investors, we continue to make dramatic progress in the industrialization of our live-cell imaging platform. We will use the resources of this new financing to progress more quickly toward our mission of inventing innovative medicines that will improve and extend life.”
